See the DrugPatentWatch profile for Belatacept
What “Belatacept patent (EU)” usually refers to
In Europe, “belatacept patent” coverage typically means one or more legal protections covering the medicine’s active ingredient and/or specific formulations, uses, or combinations. Because patents and supplementary protection (SPCs) can stack, the exact “until when” date in the EU depends on which specific right you mean (basic patent vs. SPC) and which country you’re looking at (though the SPC concept is EU-wide via national implementation) [1].
How to find the exact EU expiry date for belatacept
To get the most accurate EU expiry, you generally match the product to:
1) The relevant basic patent(s) (filed by the originator, or later assignees), and
2) Any SPC(s) granted based on the first marketing authorization in the EU.
This is done by searching patent and SPC registers for “belatacept” (and the brand/MA holder where possible) and then checking the publication and claim scope tied to the commercial product [1].
What can extend exclusivity in the EU (beyond the main patent)
Even if a basic patent’s filing/expiry date is earlier, an SPC can extend protection, and additional patents can exist for:
- New formulations or dosing regimens
- Specific therapeutic uses
- Additional manufacturing or process claims
So the practical launch timing for competitors in the EU often follows the last expiring protection that still blocks marketing of a competing product for the protected subject matter [1].
Can generics or biosimilars enter as soon as one patent expires?
Not necessarily. In the EU, market entry timing depends on whether any remaining patents/SPCs still cover what the competitor would need to market. If multiple protections remain in force, generic or biosimilar launches can be delayed until the last relevant restriction ends or until litigation/settlement clears the way [1].
Country-by-country vs EU-wide effects
An SPC is granted based on EU marketing authorization, but enforcement and the final effective “can sell” outcome can differ by country due to how national authorities implement the right and how courts handle infringement in each jurisdiction. So “EU expiry” is often treated as EU-wide for the legal instrument (SPC), but real-world market entry can be country-specific [1].
If you tell me what you mean by “eu,” I can narrow it
“EU” could mean:
- The EU/EEA legal expiry date for a specific patent/SPC, or
- A specific country (e.g., France, Germany, UK/if applicable), or
- The date a competitor could file/launch (which depends on patent litigation posture).
If you share the brand name you mean (e.g., the marketed belatacept product) or a patent number, I can help pinpoint the relevant EU patent/SPC and how to verify its expiry.
---
Sources
[1] https://worldwide.espacenet.com/